Levosimendan · Simdax

Small molecule

Also known as TNX-103

Approvedregulatory verdict

Evidence outlook

Approved: Acutely decompensated severe chronic heart failure (Simdax; 60+ countries, not the US) (SE)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:Pulmonary Hypertension due to Left Heart Disease · Phase 3 · investigational in the US

Also approved (1)
SE
  • Acutely decompensated severe chronic heart failure (Simdax; 60+ countries, not the US)
Product first approved 2000pmc.ncbi.nlm.nih.gov

Source for the program status

Company guidance: data expected the end of 2026 (Tenax Therapeutics, 31 Jul 2026). “Specifically, we plan to complete our ongoing Phase 3 LEVEL clinical trial of TNX-103 in PH-HFpEF and make public before the end of 2026 the results of the 12-week randomized treatment period.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (23)
Heart Failure
NCT04158674 · Centre Hospitalier Universitaire Dijon
2020-02-24 – 2023-10-11 · Acute Decompensated Heart Failure
What this study did
NCT03555123 · Yooyoung Pharmaceutical Co., Ltd.
2019-01-11 – 2022-07-30 · Acute Decompensated Heart Failure
What this study did
NCT03437226 · Dr. Gerhard Pölzl
2018-03-08 – 2019-12-31 · Heart Failure
What this study did
NCT02133105 · Göteborg University
2014-04 – 2017-05 · Cardiorenal Syndrome
What this study did
NCT01290146 · Niguarda Hospital
2011-02 – 2017-03 · Advanced Chronic Heart Failure
What this study did
NCT01065194 · Medical University Innsbruck
2009-08 – 2011-08 · Chronic Stable Heart Failure
What this study did
NCT00166127 · Emory University
2005-05 – 2007-01 · Heart Failure
What this study did
Pulmonary Hypertension due to Left Heart Disease
Other / comorbidity
NCT07436689 · Tenax Therapeutics, Inc.
2026-03-13 – 2029-03 · Pulmonary Hypertension Associated With HFpEF
What this study did
NCT05233202 · Assistance Publique - Hôpitaux de Paris
2023-01-23 – 2025-01-23 · Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid
What this study did
NCT06478667 · Ain Shams University
2024-12-20 – 2025-01-20 · Acute Myocarditis
What this study did
NCT04329624 · Medical University of Vienna
2020-10-10 – 2024-12-18 · Cardiovascular Risk Factor
What this study did
NCT04728932 · Assistance Publique - Hôpitaux de Paris
2021-08-27 – 2024-11-09 · Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
What this study did
NCT04020003 · Shenzhen Second People's Hospital
2019-07-01 – 2022-08-30 · ARDS, Human
What this study did
NCT03699215 · Hospital Universitario de Canarias
2018-11-17 – 2021-12-30 · ST Elevation Myocardial Infarction
What this study did
NCT03948178 · Orion Corporation, Orion Pharma
2019-06-26 – 2020-11-18 · Amyotrophic Lateral Sclerosis
What this study did
NCT03505021 · Orion Corporation, Orion Pharma
2018-06-21 – 2020-07-23 · Amyotrophic Lateral Sclerosis
What this study did
NCT02025621 · Tenax Therapeutics, Inc.
2014-07 – 2016-11 · Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
What this study did
NCT02184819 · Assistance Publique - Hôpitaux de Paris
2013-06 – 2015-11 · Coronary Artery Bypass Grafting, Left Ventricular Dysfonction
What this study did
Phase 2/3 (6)
Heart Failure
NCT07262723 · Chittagong Medical College
2025-12-01 – 2026-12-30 · Acute Decompensated Heart Failure (ADHF)
What this study did
Other / comorbidity
NCT05768230 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-03-22 – 2025-12-01 · Transesophageal Echocardiography, Acute Respiratory Distress Syndrome, Right Ventricular Dysfunction
What this study did
NCT04179604 · María de los Ángeles Tena Pajuelo
2020-06-17 – 2022-12 · Cardiac Output, Low
What this study did
NCT01720030 · VieCuri Medical Centre
2016-09 – 2017-10 · Acute Kidney Injury
What this study did
NCT01721434 · University Medical Center Nijmegen
2012-09 – 2016-05 · Muscle Weakness Conditions, Weaning Failure
What this study did
NCT00093301 · Wentworth Area Health Services
2004-10 – 2006-04 · Cardiogenic Shock, Septic Shock
What this study did
Phase 2 (17)
Heart Failure
NCT05063370 · Ain Shams University
2021-08-18 – 2022-01-01 · Right Heart Failure, Open-heart Surgery
What this study did
NCT03557255 · National Cancer Institute, Egypt
2017-08-01 – 2018-04-23 · Heart Failure
What this study did
NCT01301313 · Jose Luis Vazquez Martinez
2011-02 – 2012-02 · Acute Heart Failure
What this study did
NCT00585104 · University of Utah
2006-09 – 2008-12 · Heart Failure
What this study did
NCT00130884 · Orion Corporation, Orion Pharma
2005-03 – 2006-03 · Chronic Heart Failure, Heart Diseases
What this study did
Pulmonary Hypertension due to Left Heart Disease
NCT03624010 · Tenax Therapeutics, Inc.
2019-04-09 – 2023-04-25 · Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
What this study did
NCT03541603 · Tenax Therapeutics, Inc.
2018-11-14 – 2020-04-07 · Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
What this study did
Other / comorbidity
NCT05664191 · Assistance Publique - Hôpitaux de Paris
2023-10-13 – 2026-04-13 · Sub-arachnoid Haemorrhage
What this study did
NCT06387862 · Universitair Ziekenhuis Brussel
2024-02-01 – 2025-01 · Left Ventricular Dysfunction
What this study did
NCT06784570 · Zagazig University
2021-01-01 – 2024-08-01 · Cardiac Surgery, Low Ejection Fraction
What this study did
NCT02487407 · Orion Corporation, Orion Pharma
2015-07 – 2017-06 · Amyotrophic Lateral Sclerosis
What this study did
NCT02232399 · Göteborg University
2014-10-15 – 2017-04-25 · Congenital Heart Defects
What this study did
NCT01120106 · Bambino Gesù Hospital and Research Institute
2009-01 – 2011-09 · Low Cardiac Output Syndrome
What this study did
NCT00698763 · Orion Corporation, Orion Pharma
2008-08 – 2009-09 · Transient Ischemic Attack, Stroke
What this study did
NCT00800306 · University of Roma La Sapienza
2007-11 – 2009-04 · Septic Shock
What this study did
NCT00549107 · Ludwig Boltzmann Gesellschaft
started 2007-09 · Low Cardiac Output Syndrome
What this study did
NCT00130871 · Orion Corporation, Orion Pharma
2004-01 – 2006-01 · Coronary Heart Disease
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01576094 · Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
2009-11 – 2010-11 · Low Cardiac Output Syndrome
What this study did
Phase 4 (33)
Heart Failure
NCT06196177 · Qilu Hospital of Shandong University
2024-03-01 – 2025-02 · Heart Failure, Aortic Stenosis, Severe
What this study did
NCT04705337 · Medical University of Bialystok
2021-12-15 – 2024-08-15 · Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV, Heart Failure, Systolic, Heart Failure With Reduced Ejection Fraction
What this study did
NCT07186062 · Ain Shams University
2022-06-01 – 2024-06-01 · Acute Decompensated Heart Failure (ADHF), Cardiorenal Syndrome (CRS)
What this study did
NCT04970238 · Zhijun Sun
2021-10 – 2023-01 · ST Elevation Myocardial Infarction, Heart Failure
What this study did
NCT04573049 · China National Center for Cardiovascular Diseases
2020-09-01 – 2022-12-30 · Aortic Valve Stenosis, Heart Failure, Inotropic Agents, Safety Issues, Effect of Drug, Cardiac Event, Transcatheter Aortic Valve Replacement
What this study did
NCT04950569 · Tongji Hospital
2020-10-29 – 2022-06-30 · Heart Failure
What this study did
NCT03764722 · Collegium Medicum w Bydgoszczy
2018-08-01 – 2021-12-31 · Systolic Heart Failure
What this study did
NCT03189901 · Qilu Hospital of Shandong University
2017-07-01 – 2021-12-31 · Early Management, Acute Heart Failure, NSTEMI - Non-ST Segment Elevation MI
What this study did
NCT03576677 · Finn Gustafsson
2019-08-01 – 2020-07-30 · Heart Failure
What this study did
NCT01536132 · Parc de Salut Mar
2010-04 – 2015-11 · Heart Failure
What this study did
NCT00988806 · Hospital Universitario de Canarias
2009-11 – 2014-12 · Advanced Heart Failure
What this study did
NCT02261948 · Centro Cardiologico Monzino
2012-09 – 2014-12 · Heart Failure
What this study did
NCT01022983 · Sykehuset i Vestfold HF
2011-04 – 2012-12 · Heart Failure, Hip Fracture
What this study did
NCT00324766 · Oslo University Hospital
2006-06 – 2012-03 · Myocardial Infarction, Heart Failure, Cardiogenic Shock
What this study did
NCT00154115 · Kuopio University Hospital
2005-03 – 2008-12 · Heart Failure
What this study did
NCT00527059 · University of Roma La Sapienza
2007-10 – 2008-03 · Heart Failure, Renal Insufficiency
What this study did
NCT00219388 · Orion Corporation, Orion Pharma
2002-11 – 2005-04 · Heart Failure
What this study did
Other / comorbidity
NCT07105202 · Radboud University Medical Center
2025-09-17 – 2028-08-01 · Mechanical Ventilation, Weaning Failure
What this study did
NCT05956431 · Peking University Third Hospital
2023-08-01 – 2024-12-31 · Heart Arrest
What this study did
NCT04330755 · Dalia Saad Abd-El Kader
2021-02-04 – 2023-04-30 · Aortic Coarctation
What this study did
NCT02531724 · Sahlgrenska University Hospital
2015-09 – 2020-12 · Acute Kidney Injury, Renal Insufficiency, Acute
What this study did
NCT01500785 · Tampere University Hospital
2018-06-15 – 2019-09-11 · Myocardial Stunning
What this study did
NCT03855579 · Assiut University
2019-03-06 – 2019-09-10 · Hemodynamics
What this study did
NCT02640846 · Sahlgrenska University Hospital
2015-12 – 2019-01 · Septic Shock, Cardiomyopathy
What this study did
NCT00994825 · Università Vita-Salute San Raffaele
2009-11 – 2016-05 · Low Cardiac Output Syndrome
What this study did
NCT01595737 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2011-02 – 2014-11 · Cardiac Surgery
What this study did
NCT01318460 · AHEPA University Hospital
2011-03 – 2014-03 · Coronary Artery Disease
What this study did
NCT02012946 · Azienda Policlinico Umberto I
2013-12 – 2013-12 · Cardiovascular Diseases
What this study did
NCT01616069 · Federal University of Juiz de Fora
2012-02 – 2013-12 · Cardiopulmonary Bypass Graft
What this study did
NCT01969071 · Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
2009-07 – 2013-09 · Mitral Valve Stenosis With Incompetence or Regurgitation
What this study did
NCT01188369 · University of Aarhus
2010-09 – 2013-03 · Diastolic Dysfunction, Left Ventricular Hypertrophy
What this study did
NCT01210976 · Tampere University Hospital
2009-01 – 2010-09 · Heart Valve Disease
What this study did
NCT00610350 · University of Roma La Sapienza
2005-01 – 2007-02 · Myocardial Protection
What this study did
Early phase / not applicable (13)
Heart Failure
NCT07664748 · Niguarda Hospital
2026-10-30 – 2028-05-15 · Heart Failure
What this study did
NCT02408003 · Sahlgrenska University Hospital
2014-03 – 2017-05 · Heart Failure, Diastolic, Aortic Valve Stenosis, Monitoring, Physiologic, Physiology
What this study did
NCT01221116 · Ullevaal University Hospital
2003-01 – 2008-12 · Heart Failure, Cardiac Surgery
What this study did
Other / comorbidity
NCT07914933 · Meshalkin Research Institute of Pathology of Circulation
2025-04-29 – 2027-12 · LEVOSIMENDAN, PULMONARY THROMBOENDARTERECTOMY, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Hypertension
What this study did
NCT05222256 · Assiut University
2022-03-25 – 2024-05-25 · Open Heart Surgery
What this study did
NCT04718350 · Aretaieion University Hospital
2021-01-27 – 2023-12-30 · Hypertension, Pulmonary, Cardiac Failure, Pulmonary Vascular Resistance Abnormality
What this study did
NCT04599816 · Aretaieion University Hospital
2020-10-17 – 2022-10-17 · Hypertension, Pulmonary, Cardiac Failure, Pulmonary Vascular Resistance Abnormality
What this study did
NCT04635293 · Aretaieion University Hospital
2012-01-01 – 2020-11-09 · Cardiac Disease, Cardiac Failure, Cardiac Surgery, Inotropes, Ejection Fraction
What this study did
NCT03022877 · RWTH Aachen University
2017-06 – 2018-12 · Myocardial Infarction, Outcome
What this study did
NCT02963454 · Military Hospital of Tunis
2011-01 – 2018-02 · Septic Shock
What this study did
NCT01219712 · University Hospital, Linkoeping
2011-01 – 2013-02 · Left Ventricular Dysfunction, Femoral Fracture
What this study did
NCT01101620 · University Medical Center Nijmegen
2010-04 – 2010-09 · Respiratory Muscle Function
What this study did
NCT00695929 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2008-07 – 2009-10 · Congenital Cardiovascular Defects, Low Cardiac Output Syndrome
What this study did

Competitive landscape

This drug's own stage for Heart Failure: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Levosimendan (Simdax): this drugPhase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
AZD3427DiscontinuedPeptideRelaxin receptor (RXFP1) / relaxinWeak signal
NCT05737940: Change From Baseline in Pulmonary Vascular Resistance (PVR) (Baseline to Week 25): AZD3427 Dose 1.1 mg 1.002 Ratio (95% CI 0.862 to 1.164) | AZD3427 Dose 5.4 mg 1.221 Ratio (95% CI 1.054 to 1.415) | AZD3427 Dose 30.0 mg 0.95 Ratio (95% CI 0.815 to 1.109) | Placebo 1.056 Ratio (95% CI 0.908 to 1.228)

Large race: only the 61 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Simdax (Levosimendan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
February 2027 (1)
Phase 3Cardiogenic ShockRecruiting
Est. primary completion 2027-02-03 · NCT04020263 · CT.gov ↗
What to watch
May 2027 (1)
Early phase / not applicableHeart FailureRecruiting
Est. primary completion 2027-05-15 · NCT07664748 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Mechanical Ventilation, Weaning FailureRecruiting
Est. primary completion 2027-08-01 · NCT07105202 · CT.gov ↗
What to watch
November 2027 (1)
Early phase / not applicableLEVOSIMENDAN, PULMONARY THROMBOENDARTERECTOMY, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary HypertensionRecruiting
Est. primary completion 2027-11 · NCT07914933 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 3Pulmonary Hypertension due to Left Heart DiseaseActive not recruiting
Est. primary completion 2028-06-30 · NCT07288398 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 3Pulmonary Hypertension Associated With HFpEFEnrolling by invitation
Est. primary completion 2029-03 · NCT07436689 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 August 2026Topline resultPhase 3 LEVEL topline: primary endpoint not met
Tenax Therapeutics · Source ↗